Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):320–9.

Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. https://doi.org/10.1016/J.JAAD.2018.09.035.

Article  PubMed  Google Scholar 

Nymand L, Nielsen ML, Vittrup I, et al. Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort. Br J Dermatol. 2024;190(2):207–15. https://doi.org/10.1093/BJD/LJAD401.

Article  PubMed  Google Scholar 

Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I—systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31. https://doi.org/10.1111/JDV.18345.

Article  CAS  PubMed  Google Scholar 

Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):342–5. https://doi.org/10.1016/j.jaad.2023.08.103.

Article  PubMed  Google Scholar 

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62.

Article  CAS  PubMed  Google Scholar 

Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13–dominant disease with greater molecular heterogeneity compared to psoriasis. J Investig Dermatol. 2019;139(7):1480–9.

Article  CAS  PubMed  Google Scholar 

Witkoff B, Logas CM, Glick BP, Rosso JQ. JAK inhibitors in the treatment of atopic dermatitis. Dermatol Rev. 2022;3(1):20–8. https://doi.org/10.1002/DER2.116.

Article  Google Scholar 

Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. https://doi.org/10.1038/NRRHEUM.2015.167.

Article  CAS  PubMed  Google Scholar 

Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–3. https://doi.org/10.1242/JCS.00963.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):1. https://doi.org/10.1001/JAMADERMATOL.2020.1406.

Article  PubMed Central  Google Scholar 

Irvine AD, Prajapati VH, Guttman-Yassky E, et al. Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results through 140 weeks. Am J Clin Dermatol. 2025. https://doi.org/10.1007/S40257-025-00975-3.

Article  PubMed  PubMed Central  Google Scholar 

Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43–56.

Article  CAS  PubMed  Google Scholar 

Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149. https://doi.org/10.1007/S40265-021-01638-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfizer. Japan’s MHLW approves Pfizer’s CIBINQO® (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis . September 30, 2021. https://www.pfizer.com/news/press-release/press-release-detail/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults. Accessed 15 Sept 2025.

Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients. Healthcare. 2021;9(11):1575. https://doi.org/10.3390/HEALTHCARE9111575.

Article  PubMed  PubMed Central  Google Scholar 

Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol. 2024;192(1):36–45. https://doi.org/10.1093/BJD/LJAE404.

Article  PubMed  Google Scholar 

Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–55. https://doi.org/10.1001/JAMADERMATOL.2021.3023.

Article  PubMed  PubMed Central  Google Scholar 

Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–82. https://doi.org/10.1016/S0140-6736(22)01199-0.

Article  CAS  PubMed  Google Scholar 

Elmariah SB, Smith JS, Merola JF. JAK in the [Black] box: a dermatology perspective on systemic jak inhibitor safety. Am J Clin Dermatol. 2022;23(4):427–31. https://doi.org/10.1007/S40257-022-00701-3/TABLES/3.

Article  PubMed  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26. https://doi.org/10.1056/nejmoa2109927.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. Janus kinase (JAK) inhibitors: drug safety communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death. https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 15 Sept 2025.

European Medicines Agency. Janus kinase inhibitors (JAKi)—referral. https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki. Accessed 15 Sept 2025.

Alani O, Wang D, Wahood S, et al. Is Upadacitinib cardioprotective in chronic inflammatory diseases? A review of major adverse cardiovascular events and venous thromboembolism in atopic dermatitis. J Drugs Dermatol. 2025;24(5):530–3. https://doi.org/10.36849/JDD.9049.

Article  PubMed  Google Scholar 

Vittrup I, Thein D, Francis Thomsen S, Egeberg A, Thyssen JP. Risk factors that impact treatment with oral Janus kinase inhibitors among adult patients with atopic dermatitis: a nationwide registry study. Acta Derm Venereol. 2024. https://doi.org/10.2340/ACTADV.V104.18638.

Article  PubMed  PubMed Central  Google Scholar 

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–47. https://doi.org/10.1016/J.JAAD.2020.08.051.

Article  CAS  PubMed  Google Scholar 

Rønnstad ATM, Bunick CG, Chovatiya R, et al. Real-world evidence of tralokinumab effectiveness and safety: a systematic review and meta-analysis. Am J Clin Dermatol. 2025. https://doi.org/10.1007/S40257-025-00927-X.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1–11. https://doi.org/10.1186/S13643-021-01626-4.

Article  Google Scholar 

Study Quality Assessment Tools|NHLBI, NIH. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 22 Nov 2024.

Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(12):2537–42. https://doi.org/10.1111/JDV.19378.

Article  CAS  PubMed  Google Scholar 

Tong Z, Zhang Y, Zhou K, et al. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab. J Am Acad Dermatol. 2023;89(4):826–8. https://doi.org/10.1016/J.JAAD.2023.05.077.

Article  CAS  PubMed  Google Scholar 

Bai J, Su W, Fang H, Qiao J. Efficacy of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in real-world practice in a single center. Am J Ther. 2024;31(3):E332–4. https://doi.org/10.1097/MJT.0000000000001675.

Article  PubMed  Google Scholar 

Chen Y, Cao Q, Peng C, et al. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China. Front Med. 2024;18(4):752–6. https://doi.org/10.1007/S11684-024-1063-9/METRICS.

Article  PubMed